Nature Reviews. Drug Discovery最新文献_第7页

Vaccines for cancer prevention: exploring opportunities and navigating challenges 预防癌症的疫苗：探索机遇和应对挑战

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-12-02 DOI: 10.1038/s41573-024-01081-5

Michele Graciotti, Lana E. Kandalaft

{"title":"Vaccines for cancer prevention: exploring opportunities and navigating challenges","authors":"Michele Graciotti, Lana E. Kandalaft","doi":"10.1038/s41573-024-01081-5","DOIUrl":"10.1038/s41573-024-01081-5","url":null,"abstract":"Improved understanding of cancer immunology has gradually brought increasing attention towards cancer-preventive vaccines as an important tool in the fight against cancer. The aim of this approach is to reduce cancer occurrence by inducing a specific immune response targeting tumours at an early stage before they can fully develop. The great advantage of preventive cancer vaccines lies in the potential to harness a less-compromised immune system in vaccine recipients before their immune responses become affected by the advanced status of the disease itself or by aggressive treatments such as chemotherapy. Successful implementation of immunoprevention against oncogenic viruses such as hepatitis B and papillomavirus has led to a dramatic decrease in virally induced cancers. Extending this approach to other cancers holds great promise but remains a major challenge. Here, we provide a comprehensive review of preclinical evidence supporting this approach, encouraging results from pioneering clinical studies as well as a discussion on the key aspects and open questions to address in order to design potent prophylactic cancer vaccines in the near future. Cancer-preventive vaccines can reduce cancer occurrence by inducing a specific immune response against tumours before they can fully develop. This Review discusses results from pioneering clinical studies and potential approaches to design potent prophylactic cancer vaccines in the future.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 2","pages":"134-150"},"PeriodicalIF":122.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142760023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiviral target compound profile for pandemic preparedness 大流行防范的抗病毒靶标化合物概况

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-12-02 DOI: 10.1038/s41573-024-01102-3

James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A. T. Young, Richa Chandra, Sujata Vaidyanathan, Margaret Chu-Moyer, Christopher L. Lynch, Andrew Campbell, Kumar Singh Saikatendu, John P. Bilello, Yoshihiko Murata, Marnix van Loock, Aeron C. Hurt, Timothy Tellinghuisen, Lee Ruggiero, Richard Mackman, Nina M. Hill, John C. Pottage Jr, on behalf of the INTREPID Alliance

引用次数: 0

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) 代谢功能障碍相关性脂肪性肝炎（MASH）的治疗前景

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-28 DOI: 10.1038/s41573-024-01084-2

Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal

{"title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","authors":"Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal","doi":"10.1038/s41573-024-01084-2","DOIUrl":"10.1038/s41573-024-01084-2","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic and are driven by chronic overnutrition and multiple genetic susceptibility factors. The physiological outcomes include hepatocyte death, liver inflammation and cirrhosis. The first therapeutic for MASLD and MASH, resmetirom, has recently been approved for clinical use and has energized this therapeutic space. However, there is still much to learn in clinical studies of MASH, such as the scale of placebo responses, optimal trial end points, the time required for fibrosis reversal and side effect profiles. This Review introduces aspects of disease pathogenesis related to drug development and discusses two main therapeutic approaches. Thyroid hormone receptor-β agonists, such as resmetirom, as well as fatty acid synthase inhibitors, target the liver and enable it to function within a toxic metabolic environment. In parallel, incretin analogues such as semaglutide improve metabolism, allowing the liver to self-regulate and reversing many aspects of MASH. We also discuss how combinations of therapeutics could potentially be used to treat patients. Driven by chronic overnutrition and associated with obesity, metabolic dysfunction-associated steatotic liver disease is increasing in prevalence. This Review discusses two main therapeutic approaches: improving the metabolism with incretin mimetics such as semaglutide and directly targeting the liver with agents such as the recently approved resmetirom.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 3","pages":"171-189"},"PeriodicalIF":122.7,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-TACs target solid tumours 针对实体瘤的 Multi-TACs

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00193-2

Sarah Crunkhorn

引用次数: 0

The targeted protein degradation landscape 靶向蛋白质降解情况

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00187-0

Kelly Farley, Souparno Bhattacharya, Jon Cleland, Priya Chandran, John Wu

引用次数: 0

Understanding cholestatic itch 了解胆汁淤积性瘙痒

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00191-4

Sarah Crunkhorn

引用次数: 0

ENGases to treat IgG-mediated diseases 治疗 IgG 媒介疾病的 ENGases

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00190-5

Sarah Crunkhorn

引用次数: 0

Author Correction: Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets 作者更正：给 NLRP3 炎症小体下药：从信号机制到治疗靶点

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/s41573-024-01104-1

Lieselotte Vande Walle, Mohamed Lamkanfi

引用次数: 0

Expanding the ligandable proteome 扩展可配体蛋白质组

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00192-3

Sarah Crunkhorn

引用次数: 0

FDA approves first biparatopic antibody therapy 美国食品和药物管理局批准首个双抗体疗法

IF 122.7 1区医学

Nature Reviews. Drug Discovery Pub Date : 2024-11-26 DOI: 10.1038/d41573-024-00189-y

Asher Mullard

引用次数: 0